AbCellera Biologics Inc. (ABCL) vs Viking Therapeutics, Inc. (VKTX)

AbCellera Biologics Inc. and Viking Therapeutics, Inc. are both Biotechnology companies. AbCellera Biologics Inc. and Viking Therapeutics, Inc. are of similar size ($4.3B and $4.2B). Viking Therapeutics, Inc. has the higher net margin (0.00% vs −248.8%) and the higher return on invested capital (0.00% vs −42.5%). Across the 13 metrics below, AbCellera Biologics Inc. leads on 8 and Viking Therapeutics, Inc. on 5.

Valuation

Metric ABCL VKTX Biotechnology median
P/E n/m n/m 7.88
P/S 58.69 n/m 11.47
P/B 4.33 10.13 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 51.37 n/m 10.73
Earnings yield (4.25%) (13.10%) (28.84%)
Free cash flow yield (3.16%) (10.12%) (23.03%)

Profitability

Metric ABCL VKTX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (340.25%) 0.00% 0.00%
Net margin (248.82%) 0.00% 0.00%
Free cash flow margin (180.84%) 0.00% 0.00%
Return on equity (17.30%) (88.85%) (57.72%)
Return on assets (12.15%) (79.24%) (49.22%)
Return on invested capital (42.52%) 0.00% 0.00%

Growth

Metric ABCL VKTX Biotechnology median
Revenue growth (TTM) 101.29% — 5.64%
EPS growth (last fiscal year) 10.91% (215.84%) —
Revenue growth, 5-year CAGR (20.27%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABCL VKTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.77 4.72 4.73
Net debt to EBITDA 2.97 1.76 0.96

Dividend

Metric ABCL VKTX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ABCL VKTX Biotechnology median
Market cap 4.15b 4.31b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack